How Much Does Mounjaro Cost in 2026? (With and Without Insurance)

Pricing Detail

What Determines the Price

Mounjaro (tirzepatide) is the dual GIP/GLP-1 agonist manufactured by Eli Lilly for type 2 diabetes in adults and children 10 and older.^[1]

Four factors drive the bill: (1) whether you buy self-pay through LillyDirect, where Mounjaro pens start at $499/month at every dose;^[4] (2) insurance status and formulary tier; (3) the diagnosis on the prescription, since type 2 diabetes is covered far more broadly than off-label weight loss (Zepbound is the weight-loss-indicated alternative); and (4) whether the Mounjaro Savings Card or a patient assistance program applies.

Coverage

Insurance Coverage Requirements

Commercial insurance: most plans cover Mounjaro for type 2 diabetes when prior authorization criteria are met — typically a documented diabetes diagnosis, an HbA1c above a plan-defined threshold, and prior trial or contraindication to first-line oral agents (metformin most often). Copays vary by plan and formulary tier.

Medicare Part D: covers Mounjaro for type 2 diabetes only. The 2026 Part D out-of-pocket cap of $2,100^[6] substantially reduces annual cost for high-utilizers. Medicare does not cover Mounjaro when prescribed solely for weight loss.

Off-label weight loss: most commercial plans deny Mounjaro when the diagnosis is obesity rather than diabetes. Patients seeking tirzepatide for weight management should pursue Zepbound, which is FDA-approved for chronic weight management and obstructive sleep apnea.^[2]

Manufacturer Programs

Manufacturer Savings Programs

Mounjaro Savings Card: for commercially insured patients with a type 2 diabetes prescription and prior authorization, the savings card can reduce out-of-pocket cost to as little as $25 for up to a 3-month prescription (max savings $150/month, $1,950/year; card expires 12/31/2026).^[5]

Through LillyDirect, self-pay Mounjaro pens start at $499/month at every dose; the Mounjaro Savings Card also offers as low as $499/month for people whose insurance doesn't cover it.^[4][5]

Patient assistance: the Lilly Cares Foundation offers needs-based assistance for uninsured patients who meet income criteria. Approval is not guaranteed and the application process takes weeks.

What to Avoid

Why Compounded Tirzepatide Is Cheaper — and Riskier

Compounded tirzepatide marketed by online clinics and med-spas is often the cheapest tirzepatide on the market — and the least medical. These products are not FDA-approved.

The FDA removed tirzepatide from the drug shortage list in late 2024, sharply narrowing the legal basis for routine compounding.^[9] The agency has documented dosing errors, adverse events, and salt-form and impurity issues in compounded incretin products.^[8] What you save in dollars, you risk in product quality, dose accuracy, and the absence of physician supervision.

If brand Mounjaro is unaffordable for a diabetes indication, the better-medicine path is usually an insurance appeal, the Mounjaro Savings Card, or LillyDirect self-pay pens — not a compounded vial of unknown provenance.

Physician-Supervised Care

What a Physician-Supervised Program Includes — and What That Costs

The medication is only part of the bill. A real Mounjaro program — the kind Haute MD physicians build — also pays for the medicine around it: baseline labs, body composition, nutrition therapy, training programming, and quarterly reassessment.

The figures below are editorial estimates: typical ranges reported by practices, not a national average.

• ·New-patient consult and intake: typically $300–$750 cash, often covered as an office visit by commercial insurance.
• ·Baseline lab panel (CBC, CMP, HbA1c, lipid panel, TSH, vitamin D, hormone panel where indicated): $150–$600 cash, often covered by insurance with appropriate diagnosis codes.
• ·Body-composition assessment (DEXA or clinical-grade bioimpedance): $75–$250 per scan; quarterly is standard.
• ·Nutrition therapy with a registered dietitian: $125–$300 per visit; some plans cover medical nutrition therapy for obesity or diabetes.
• ·Follow-up visits during titration (monthly for the first 4–6 months): $150–$400 each cash, or a standard copay with insurance.
• ·Bundled concierge GLP-1 programs in major markets typically run $400–$900 per month on top of the medication, including unlimited messaging, structured nutrition and training support, and quarterly labs and DEXA.

These costs separate medical weight loss from a $200/month compounded vial. A physician-led Mounjaro program is a treatment for a chronic disease — priced and structured accordingly.